What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Cancer
- Disease
His primary areas of study are Internal medicine, Multiple myeloma, Surgery, Gastroenterology and Transplantation.
The concepts of his Internal medicine study are interwoven with issues in Immunology and Oncology.
His Multiple myeloma study combines topics in areas such as Disease and Intensive care medicine.
His Gastroenterology research includes elements of Neutropenia, Risk factor, Pathology, Hazard ratio and Myeloma protein.
His work deals with themes such as Organomegaly, Natriuretic peptide, Stem cell and Chemotherapy, which intersect with Transplantation.
His study looks at the intersection of Lenalidomide and topics like Bortezomib with Regimen.
His most cited work include:
- Improved survival in multiple myeloma and the impact of novel therapies (1718 citations)
- Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients (768 citations)
- Revised Prognostic Staging System for Light Chain Amyloidosis Incorporating Cardiac Biomarkers and Serum Free Light Chain Measurements (508 citations)
What are the main themes of his work throughout his whole career to date?
His primary scientific interests are in Internal medicine, Multiple myeloma, Surgery, Oncology and Gastroenterology.
His research related to Transplantation, Autologous stem-cell transplantation, Lenalidomide, Amyloidosis and Cohort might be considered part of Internal medicine.
In his study, which falls under the umbrella issue of Amyloidosis, Hematologic Response is strongly linked to AL amyloidosis.
His Multiple myeloma research is multidisciplinary, incorporating perspectives in Newly diagnosed, Stem cell and Dexamethasone.
His work carried out in the field of Stem cell brings together such families of science as Mutation and Immunology.
His Gastroenterology study integrates concerns from other disciplines, such as Survival rate, Bone marrow and Very Good Partial Response.
He most often published in these fields:
- Internal medicine (61.85%)
- Multiple myeloma (45.56%)
- Surgery (27.42%)
What were the highlights of his more recent work (between 2017-2021)?
- Internal medicine (61.85%)
- Multiple myeloma (45.56%)
- Oncology (22.38%)
In recent papers he was focusing on the following fields of study:
Internal medicine, Multiple myeloma, Oncology, Amyloidosis and Gastroenterology are his primary areas of study.
His work on AL amyloidosis, Autologous stem-cell transplantation, Cohort and Transplantation is typically connected to In patient as part of general Internal medicine study, connecting several disciplines of science.
His Transplantation study deals with the bigger picture of Surgery.
His study in Multiple myeloma is interdisciplinary in nature, drawing from both Newly diagnosed, Progression-free survival and Bone marrow.
His studies examine the connections between Oncology and genetics, as well as such issues in Dexamethasone, with regards to Refractory.
His Gastroenterology research integrates issues from Survival rate, Waldenstrom macroglobulinemia and Hazard ratio.
Between 2017 and 2021, his most popular works were:
- Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria. (67 citations)
- Selective Inhibition of Nuclear Export With Oral Selinexor for Treatment of Relapsed or Refractory Multiple Myeloma (67 citations)
- Daratumumab-based therapy in patients with heavily-pretreated AL amyloidosis (46 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Cancer
- Disease
The scientist’s investigation covers issues in Internal medicine, Multiple myeloma, Gastroenterology, AL amyloidosis and Amyloidosis.
In Internal medicine, David Dingli works on issues like Oncology, which are connected to Anemia.
His Multiple myeloma research incorporates themes from Stage, Newly diagnosed and Hazard ratio.
His Gastroenterology study also includes
- Hematopoietic stem cell transplantation which intersects with area such as Melphalan,
- Waldenstrom macroglobulinemia together with Complication.
David Dingli combines subjects such as Cardiology, Survival rate, Urology, Retrospective cohort study and Proteinuria with his study of AL amyloidosis.
His Amyloidosis research includes themes of Immunoglobulin light chain, Immunoglobulin Light-chain Amyloidosis, Bone marrow and Hematologic Response.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
